COMPANY INTELLIGENCE PROFILE
4BASECARE ONCO SOLUTIONS PRIVATE LIMITED
4Basecare Onco Solutions (brand: 4baseCare) is a precision-oncology company using next-generation sequencing (NGS), genomics and digital-health tools for cancer biomarker testing and therapy selection.
Business Overview
4Basecare Onco Solutions (brand: 4baseCare) is a precision-oncology company using next-generation sequencing (NGS), genomics and digital-health tools for cancer biomarker testing and therapy selection. Its genomic panels include Indiegene, marketed as an India-population-specific cancer gene panel for biomarker testing. Founders Hitesh Goswami and Kshitij Rishi started the 4baseCare brand in 2018; this Indian legal entity was incorporated in September 2020 as a subsidiary of a foreign parent. Reported headcount ~156 (Mar 2025). [GenomeWeb, IndianStartupNews, TheCompanyCheck]
Sector & Classification
Human health activities — oncology clinics / cancer diagnostics & treatment. CIN activity code U85100 (human health activities); reported as hospital & medical care / oncology testing. [Tofler, TheCompanyCheck]
Directors & Key Management
Directors — source notes
Kshitij Datta Rishi (DIN 06442992), appointed 03 Sep 2020; Hitesh Madan Goswami (DIN 03556183), appointed 03 Sep 2020. DINs from a single source (Tofler) — partial. Both also sit on boards of 4Basecare Genomics Pvt Ltd, 4Basecare Precision Health Pvt Ltd and Biokart India Pvt Ltd. [Tofler; TheCompanyCheck]
GST Registrations
not obtained — no individual GSTIN page could be retrieved from a permitted source (knowyourgst individual page 404/blocked). PAN also not obtained (would be embedded in GSTIN). Company is Karnataka-registered (GST state code 29 expected). Number of registrations and status: not obtained.
Financials
Standalone (unaudited aggregation from directory sources; treat as indicative, not primary filings). FY2025 (year ended 31 Mar 2025): Operating revenue ≈ ₹3.12 crore, reported down ~74% YoY [TheCompanyCheck]; Tofler corroborates a ~-74.0% total-revenue decline and a ~-98.9% decline in total assets at Mar 2025 [Tofler]. FY2024 operating revenue was reported in the ₹1cr–₹100cr band (exact figure behind paywall) [Tofler]. EBITDA, PAT, net worth and borrowings: not obtained (behind premium paywall). The steep revenue and asset drop suggests business/assets may have shifted to a sister entity — unverified; flag for confirmation.
Funding History
CAUTION — entity-attribution trap. Public funding coverage is reported against the "4baseCare" brand/group, NOT confirmed against this specific CIN (U85100KA2020FTC138091); the recipient may be a sister/parent entity (e.g., 4Basecare Genomics Pvt Ltd or the foreign parent). Brand-level rounds reported: pre-Series A ~$2M (consortium of VCs, via PR Newswire); Series A $6M led by Yali Capital (GenomeWeb, 2023-24); Series B first close Rs 90 crore (investors incl. Ashish Kacholia, Lashit Sanghvi, Yali Capital); Series B second close/top-up Rs 38 crore led by growX Ventures and Infosys, taking Series B to ~Rs 128 crore (~$13.3M) [Entrackr, Jun 2026]. Tracxn cites cumulative ~$25.9M across ~8 rounds (Tracxn used for round names only). [GenomeWeb, Entrackr, SiliconIndia, PR Newswire]
Loans & Charges
None found — no open/registered charges and no secured borrowings reported. [TheCompanyCheck]
Credit Ratings
None found — no CRISIL, ICRA or CARE rating located for this entity.
Legal & Compliance
None found — Indian Kanoon search returned zero matching cases for the company. [indiankanoon.org]
Competitive Landscape
MedGenome (large — market leader, ~45% genomic-testing share); Strand Life Sciences (mid — clinical genomics/oncology); Karkinos Healthcare (mid — NGS-led oncology network); Datar Cancer Genetics (mid — molecular oncology, UK+India labs); Mapmygenome (small–mid — consumer/clinical genomics); Core Diagnostics (mid — oncology diagnostics). [GenomeWeb, ANI, Nexdigm market report]
Frequently Asked Questions
What does 4BASECARE ONCO SOLUTIONS PRIVATE LIMITED do?
4Basecare Onco Solutions (brand: 4baseCare) is a precision-oncology company using next-generation sequencing (NGS), genomics and digital-health tools for cancer biomarker testing and therapy selection.
What is the CIN of 4BASECARE ONCO SOLUTIONS PRIVATE LIMITED?
4BASECARE ONCO SOLUTIONS PRIVATE LIMITED's Corporate Identification Number (CIN) is U85100KA2020FTC138091.
When was 4BASECARE ONCO SOLUTIONS PRIVATE LIMITED incorporated?
4BASECARE ONCO SOLUTIONS PRIVATE LIMITED was incorporated on 03 September 2020 and is registered with RoC-Bangalore (Karnataka).
Who are the directors of 4BASECARE ONCO SOLUTIONS PRIVATE LIMITED?
Directors on record include Kshitij Datta Rishi (DIN 06442992); Hitesh Madan Goswami (DIN 03556183).
Where is 4BASECARE ONCO SOLUTIONS PRIVATE LIMITED registered?
The registered office of 4BASECARE ONCO SOLUTIONS PRIVATE LIMITED is at c/o Institute of Bioinformatics and Applied Biotechnology (IBAB), Biotech Park, Electronics City Phase 1, Bangalore, Karnataka, India – 560100 [Tofler, TheCompanyCheck].
Information compiled from public registry and secondary sources (as of 2026-07-28). It may be incomplete or dated; verify independently before relying on it. Known gaps: GSTIN, PAN, exact EBITDA/PAT/net worth/borrowings, precise FY2024/FY2025 revenue figures, full shareholding split, and confirmation of which legal entity received the funding rounds are all not obtained (paywalled or unresolved). DINs confirmed by only one source. Funding attribution to this exact CIN is unverified.